Barclays Maintains Overweight on Sotera Health, Lowers Price Target to $20

Benzinga · 3d ago
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and lowers the price target from $22 to $20.